Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients

References

• NawataMSaitoKNakayamadaSTanakaYDiscontinuation of infliximab in rheumatoid arthritis patients in clinical remissionMod Rheumatol200818546046418535759
   PubMed Web of Science ®Google Scholar
• TanakaYHirataSFukuyoSDiscontinuation of adalimumab without functional and structural progress after attaining remission in patients with rheumatoid arthritisArthritis Rheum2011632468
   Google Scholar
• FuchsHAKayeJJCallahanLFNanceEPPincusTEvidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of diseaseJ Rheumatol19891655855912754663
   PubMed Web of Science ®Google Scholar
• CrossMSmithEHoyDThe global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 studyAnn Rheum Dis20147371316132224550173
   PubMed Web of Science ®Google Scholar
• LajasCAbasoloLBellajdelBCosts and predictors of costs in rheumatoid arthritis: a prevalence-based studyArthritis Rheum2003491647012579595
   PubMed Web of Science ®Google Scholar
• SchoelsMWongJScottDLEconomic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis2010696995100320447950
   PubMed Web of Science ®Google Scholar
• KavanaughASmolenJSThe when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trialsClin Exp Rheumatol2013314 Suppl 78S19S2124129131
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Welfare, National Health Insurance Administration, Secondary National Health Insurance AdministrationDrug payment regulations Available from: http://www.nhi.gov.tw/webdata/webdata.aspx?menu=18&menu_id=683&webdata_id=2919Accessed June 15, 2017
   Google Scholar
• González-ÁlvaroIMartínez-FernándezCDorantes-CalderónBSpanish Rheumatology SocietySpanish Rheumatology SocietySpanish Rheumatology Society and Hospital Pharmacy Society consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisRheumatology (Oxford)20155471200120925526976
   PubMed Web of Science ®Google Scholar
• YoshidaKSungYKKavanaughABiologic discontinuation studies: a systematic review of methodsAnn Rheum Dis201473359559923723316
   PubMed Web of Science ®Google Scholar
• LunnDJThomasABestNSpiegelhalterDWinBUGS - a Bayesian modelling framework: concepts, structure, and extensibilityStat Comput2000104325337
   Web of Science ®Google Scholar
• BeresniakAAriza-ArizaRGarcia-LlorenteJFRamirez-ArellanoADupontDModelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in SpainInt J Inflam2011201172763421785694
   PubMedGoogle Scholar
• SmolenJSEmeryPFleischmannRAdjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialLancet2014383991432133224168956
   PubMed Web of Science ®Google Scholar
• ChatzidionysiouKAsklingJErikssonJKristensenLEvan VollenhovenRARTIS groupEffectiveness of TNF inhibitor switch in RA: results from the national Swedish registerAnn Rheum Dis201574589089624431398
   PubMed Web of Science ®Google Scholar
• HirataSSaitoKKuboSDiscontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational studyArthritis Res Ther2013155R13524286472
   PubMed Web of Science ®Google Scholar
• TanakaYHirataSKuboSDiscontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR studyAnn Rheum Dis201574238939524288014
   PubMed Web of Science ®Google Scholar
• SmolenJSNashPDurezPMaintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialLancet2013381987091892923332236
   PubMed Web of Science ®Google Scholar
• EmeryPHammoudehMFitzgeraldOAssessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the PRIZE studyAnn Rheum Dis201372Suppl 3A399
   Google Scholar
• van VollenhovenRFFranck-LarssonKLeirisalo-RepoMIn rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept at 50 mg or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-arm, double-blind studyAnn Rheum Dis201372Suppl 3A434A435
   Google Scholar
• YamanakaHSetoYNagaokaSDiscontinuation of etanercept in early rheumatoid arthritis patients who have achieved sustained remission: results of the randomized controlled trial in period 2 of the ENCOURAGE studyAnn Rheum Dis201473Suppl 2239
   Web of Science ®Google Scholar
• GreenbergJDShanYReedGWBitmanBCollierDComparison of switching to reduced dose vs continuation of standard dose etanercept for rheumatoid arthritis patients in the CORRONA registryAnn Rheum Dis201473Suppl 2241
   Web of Science ®Google Scholar
• CampbellRCSandersELeoneFGilgeoursESibleyMKielyPDThe cost savings associated with a departmental etanercept dose reduction pathway for patients with rheumatic diseases and maintained low disease activityArthritis Rheum201365Suppl 10487
   Google Scholar
• KamiyaMSohenSKikuchiHAssessment of etanercept withdrawal in rheumatoid arthritis patients in remissionAnn Rheum Dis201170Suppl 341421131643
   PubMed Web of Science ®Google Scholar
• UrataYNakamuraYMotomuraSDiscontinuation of etanercept in rheumatoid arthritis patients in clinical remission: two-year outcomeAnn Rheum Dis201271Suppl 3525
   Google Scholar
• TanakaYTakeuchiTMimoriTMiyasakaNKoikeTRRR study investigatorsThe possibility and predictive factors of maintaining low disease activity and joint structure after discontinuation of infliximab in RA patients: results from 3-year experience of RRR studyAnn Rheum Dis201372Suppl 3A443
   Google Scholar
• BrocqOMillasseauEAlbertCEffect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritisJoint Bone Spine200976435035519362504
   PubMed Web of Science ®Google Scholar
• PhamTMorelJAlfaiateTPredictive factors of relapse or persistent stable remission for rheumatoid arthritis (RA) patients in remission in a TNF blocker-spacing strategy trial (STRASS trial)Arthritis Rheum201365Suppl 10S1021
   Google Scholar
• van der BroekMKlarenbeekNBDirvenLDiscontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt studyAnn Rheum Dis20117081389139421515916
   PubMed Web of Science ®Google Scholar
• SmolenJSBreedveldFCBurmesterGRTreating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnn Rheum Dis201675131525969430
   PubMed Web of Science ®Google Scholar
• WelsingPMLandewéRBvan RielPLThe relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysisArthritis Rheum20045072082209315248205
   PubMed Web of Science ®Google Scholar
• SacristánJAOlivaJDel LlanoJPrietoLPintoJLWhat is an efficient health technology in Spain?Gac Sanit2002164334343 Spanish [with English abstract]12113733
   PubMedGoogle Scholar